


# Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors


This article was published in the following Dove Press journal:  
*Drug Design, Development and Therapy*

Xiaohua Guo \*

Zhaowen Liu \*

Yizhou Zheng 

Yamei Li 

Linfu Li 

Hai Liu 

Zhixi Chen 

Longhuo Wu 

College of Pharmacy, Gannan Medical University, Ganzhou 341000, People's Republic of China

\*These authors contributed equally to this work

**Abstract:** Transthyretin (TTR) is a tetrameric protein, and its dissociation, aggregation, deposition, and misfolding are linked to several human amyloid diseases. As the main transporter for thyroxine (T4) in plasma and cerebrospinal fluid, TTR contains two T4-binding sites, which are docked with T4 and subsequently maintain the structural stability of TTR homotetramer. Affected by genetic disorders and detrimental environmental factors, TTR degrades to monomer and/or form amyloid fibrils. Reasonably, stabilization of TTR might be an efficient strategy for the treatment of TTR-related amyloidosis. However, only 10–25% of T4 in the plasma is bound to TTR under physiological conditions. Expectedly, T4 analogs with different structures aiming to bind to T4 pockets may displace the functions of T4. So far, a number of compounds including both natural and synthetic origin have been reported. In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein.


**Keywords:** transthyretin, amyloidogenesis, stabilization, inhibitors

## Introduction

Transthyretin (TTR), functions as a mediator in transporting thyroxine (T4) in the cerebrospinal fluid and plasma,<sup>1</sup> is a 55 kDa homotetrameric protein composed of 127 amino acid residues in each monomer, which consists of two four-stranded  $\beta$ -sheets. Strands DAGH and CBEF are the  $\beta$ -sheets, and they are extended in the dimer to be DAGHH'G'A'D' and CBEFF'E'B'C', standing for their individual monomers. Hydrogen bonds between the main-chain atoms and strand H from different dimers promote the association of two dimers, forming a tetramer.<sup>2</sup> The contact areas in monomer-monomer and dimer-dimer are extensive in TTR. More than 120 TTR mutations have been associated with amyloidogenesis and diseases. Investigation on the roles of some specific amino acids, such as T119M,<sup>2</sup> V30M,<sup>3</sup> and R104H,<sup>4</sup> has been conducted. The A25T-TTR variant is among the most destabilized and fastest dissociating TTR tetramers.<sup>5</sup> Tetramer stability is mainly governed by hydrophobic interactions, and the subunits exchange among TTR may occur faster at 4°C than at 25°C or 37°C.<sup>6</sup>

The tetramer structure of TTR contains two funnel-shaped T4-binding sites, and binding of T4 may maintain the stability of the TTR tetramer structure.<sup>7,8</sup> Structurally, TTR is a homotetramer with an extensive  $\beta$ -sheet structure, and the two identical T4-binding sites locate at the dimer–dimer interfaces (Figure 1).<sup>9–15</sup> Specifically, two T4 molecules, with different orientations, bind to the unique

Correspondence: Longhuo Wu  
Email longhuo@hotmail.com



**Figure 1** Crystal structure (PDB ID: 1IE4) of TTR tetramer with T4 interacting with the two T4-binding sites is shown. **(A)** The two T4-binding sites located at the dimer-dimer interfaces are framed by the white boxes. **(B)** The specific interaction between T4 and amino acids at the binding pockets is shown. The yellow rod structure is indicated as T4, and the green solid lines are hydrogen bonds. These pictures are prepared using the program UCSF Chimera developed by the University of California.

binding sites between AC and BD dimers (Figure 1A), bridging these subunits. Within the binding cavity, some key amino acids (Glu54, Lys15, Leu17, Ala108, Thr119, Leu110, Ser117) (Figure 1B) from the corresponding monomer are orchestrated to form halogen-binding pockets P1, P2, and P3 (Table 1). The amino- and carboxyl-terminal structures of T4 form hydrogen bonds by interacting with Glu54 and Lys15, respectively, in the P1 binding pocket.<sup>16</sup> Interaction of ligands with T4-binding sites is dominantly enforced by the hydrophobic effect and electrostatic interactions, which promote kinetic stabilization in the weaker dimer-dimer interface, stabilizing TTR tetramer, and increasing the kinetic barrier for dissociation.<sup>16,17</sup>

However, most of TTRs T4-binding cavities are unoccupied, only less than 25% of which in plasma is binding to T4. Therefore, under certain conditions (such as genetic mutation and induction by some chemical pollutants), TTR tetramer without T4 may become instability, dissociation into monomer, and misfolding, leading to initiation of oligomerization processes of monomeric TTR and formation of amyloid fibrils (Figure 2), and induction of transthyretin amyloidogenesis (ATTR), and activation of NF- $\kappa$ B signaling pathway, inflammatory stress, and cell death.<sup>18</sup> A number of mutations in the gene encoding TTR protein have been identified in elderly individuals, and a conformational change in mutated TTR tetramer is observed, which results in the deposition of amyloid fibrils and induction of several diseases, such as familial amyloid polyneuropathies (FAP), familial amyloid cardiomyopathy (FAC), and senile systemic amyloidosis (SSA).<sup>19</sup> One of the possible environmentally etiological factors might be the inheritance from parents with TTR mutations. In addition, any pollutants

may directly or indirectly affect the complex stability by, at least in partial, inducing genetic mutations. Under normal physiological conditions, clusterin is a plasma chaperone and may recognize exposed hydrophobic regions of misfolded protein, preventing them from aggregation (Table 1). Clusterin has been demonstrated to form a complex with a monomeric or oligomeric  $\beta$ -sheet rich structure of TTR in a stable manner, preventing TTR amyloid fibril formation.<sup>20</sup>

The stabilization of TTR tetramer by small molecules like T4 and T4 analogs, which interact with the binding pockets, is a promising therapeutic strategy against ATTR.<sup>21</sup> This article will review the categories and structures of ATTR inhibitors.

## Potent Inhibitors of ATTR

In the past few decades, a large number of small molecules with the activity of stabilizing the TTR tetramer structure have been reported. Most of these compounds contain a substructure with two aromatic rings by a linker. The bisaryl structures with a linker form the possible pharmacophoric elements, which have been indicated in Figure 3. In addition, other compounds with different characteristic structures also show strong activity in the stabilization of TTR tetramer, such as flavonoids, crown ethers, and carboranes, although they bind to the T4-binding sites in different manners. Inhibitors with disaggregating TTR amyloid fibrils also play an important role for managing ATTR.

## Bisaryl Structures with a Linker

The substructure-combinational strategy has been used for producing potent and selective TTR stabilizers (Figure 3). The groups including aryl-X and aryl-Z rings as well as

**Table I** The Structure–Activity Relationship of TTR Amyloidogenesis Inhibitors

Category	Compounds	SAR	References
T4	T4	Key interacting residues Glu54, Lys15, Leu17, Ala108, Thr119, Leu110, Ser117 in the binding sites; occupies halogen-binding pockets P1, P2, and P3.	[16]
Bisaryl structures with a linker	Bisaryl structures	Thyroid hormone-like substitution (3,5-X-4-OH, where X=CH <sub>3</sub> , F, Cl, Br, and I) produces potency; The linker Y designed as non-polar E-olefin or –CH <sub>2</sub> CH <sub>2</sub> - group also generates high selection.	[22]
		Position 2.6; 2.5; 2; 3,4,5 and 3.5 substitutions generate excellent potency and selectivity, and the efficacy scores are 0.789, 0.748, 0.734, 0.697 and 0.538, respectively.	[24]
	Diflunisal	Reaches the maximal therapeutic concentration of 224 μM in vitro, leading to 0.85 eq of drug bound to TTR.	[26]
	Flurbiprofen	Flank on both sides by the hydrophobic side chains of Lys15, Leu17, Ala108, Leu110, Ser117, Thr119, and Val121; The substituted phenyl ring forms interacts with Val17 and Ala108. CH <sub>3</sub> CHCOOH substituent interacts with Lys15.	[27]
	Bromodiflunisal	The binding potencies with values of 0.85 and 0.53, respectively, calculated by EC <sub>50</sub> T4/EC <sub>50</sub> tested compound, compared with that of T4 (the value of 1).	[29]
	Iododiflunisal	Interacts with Leu17, Thr106, Ala108, Thr119, and Val121. The value of EC <sub>50</sub> (T4)/EC <sub>50</sub> (I) is 0.7, compared with that of T4 (the value of 1).	[30]
	PCBs, OH-PCBs	Bind to TTR tetramer with K <sub>i</sub> values of 10–140 nM, similar to the natural ligand T4 (a K <sub>i</sub> value of 62 nM)	[37]
	LC-PCB sulfates	Produces hydrogen bonding between the sulfate groups and Lys15. Binds to TTR with equilibrium dissociation constants in the range of 4.8–16.8 nM, similar to that for T4 with 4.7 nM.	[46]
Flavonoids	Flavonoid	The more hydroxyl groups, the lower the conversion degree to amyloid fibrils.	[60]
	Apigenin	Exhibits the conversion value of 6% at the concentration of 10.8 μM and completely inhibiting fibril formation at 36 μM. Inhibits TTR disaggregation with an IC <sub>50</sub> value of 10.3 μM, compared with T4 with IC <sub>50</sub> value of 4.34 μM.	[60]
	Luteolin	In V30M TTR, Lut inhibits TTR disaggregation with an IC <sub>50</sub> value of 5.68 ± 1.10 μM, compared with that in the wild type of TTR with an IC <sub>50</sub> value of 6.38 ± 1.17 μM,	[63,64]
β-amin-oxypropionic acids	Compounds <b>283–299</b>	Different from T4, the aromatic ring is mainly docked into P3 and interacts with the residues near Ser117 and Lys15 and plays a role in deciding the binding mode.	[68]
Crown Ethers	Compounds <b>315</b>	Inhibit the formation of TTR-related amyloid fibril by 58% (at a concentration of 2 mM). Different from T4 in inhibiting mechanism, Compounds <b>315</b> located on the surface of TTR to stabilize the tetramer.	[70]
	Compounds <b>317</b>	Inhibit the formation of TTR-related amyloid fibril by 47% (at a concentration of 10 mM). Different from T4 in inhibiting mechanism, Compounds <b>317</b> located on the surface of TTR to stabilize the tetramer.	[15]
Oxazoles	Compounds <b>327</b>	A carboxyl group at C-4 demonstrates efficiency in inhibiting TTR amyloidogenesis. Substitution of ethyl, propyl, or CF <sub>3</sub> group at C-5 enhances the inhibiting activity.	[77]
γ-Mangostin	γ-Mangostin	Inhibit the amyloid fibril formation of V30M amyloidogenic TTR with EC <sub>50</sub> value of 7 ± 0.6 μM. X-ray crystallographic analysis reveals a novel diagonal model for binding to T4-binding sites, associating with two chloride ions.	[78]

(Continued)

Table 1 (Continued).


Category	Compounds	SAR	References
Quinoline	Compound <b>329</b>	Inhibits TTR fibril formation with an IC <sub>50</sub> value of 1.49 μM against wild-type TTR and 1.63 μM against V30M TTR variant. Exhibit 80% inhibition against more amyloidogenic V30M-TTR at a concentration equal to the V30M-TTR tetramer over a 120 h time course.	[79]

the linker-Y can be varied in generating alternative ATTR inhibitors (Table 1).<sup>22</sup> Structure–activity relationship (SAR) study indicates that the Y linker optimization must be in concert with SAR data from aryl-X and aryl-Z optimization to predict potential structures for selective TTR amyloidogenesis inhibition. The linker (Y) can be formed by variable chemical structures with different lengths, and both the two aryl rings (X and Z) bear a combination of substituents, including alkyl, carboxyl, halide, trifluoromethyl or hydroxyl groups (Table 1).<sup>23,24</sup> Structural optimization for better activities is focusing on aryl-X, -Z, and Y. Thyroid hormone-like substitution (3,5-X-4-OH, where X=CH<sub>3</sub>, F, Cl, Br, and I) produces potent selective TTR amyloidogenesis inhibitors. The linker Y structure is designed as non-polar *E*-olefin or –CH<sub>2</sub>CH<sub>2</sub>-group also generates highly selective inhibitors, and the hydrophobic effect of linker Y contributes to binding energy. Similar to that of T4, the binding mode of these compounds to the binding pockets has been indicated that


two aromatic rings occupy P1 and P3 pockets, respectively, and the linkers occupy the P2 pocket.<sup>25</sup> A series of ATTR small molecular inhibitors with two aromatic rings and the linkers have been designed and synthesized, which will be described below.

Under physiological conditions, T4 (**1**, Figure 4) with a diphenyl ether structure maintains the stability of TTR tetramer by binding to the T4-binding sites within TTR protein. Fenoprofen (**2**, Figure 4), a non-steroidal anti-inflammatory drug (NSAID), is also a diphenyl ether structure compound. The activity of Fenoprofen in inhibiting amyloid fibril formation has been evaluated with a maximal therapeutic concentration of 96 μM (Table 1).<sup>26</sup> Diflunisal reaches the maximal therapeutic concentration of 224 μM with 0.85 equiv of drug bound to TTR. Similarly, flufenamic acid reaches 54 μM with 0.59 equiv. Increasing amount of molecules with diphenyl ether structure has been explored (**3–12**, Figure 4). All of these compounds show a high affinity to TTR protein and prevent against fibrillogenesis by stabilizing the tetramer structure of TTR.<sup>18</sup>


Similarly, diphenyl compounds can also bind to T4-binding sites, stabilizing TTR tetramer. A variety of NSAIDs with diphenyl groups, such as diflunisal (**13**, Figure 5) and flurbiprofen (**14**, Figure 5), have been identified to contribute to the stability of TTR tetramer (Table 1).<sup>27,28</sup> Specifically, the biaryl moiety of flurbiprofen is flanked on both sides by the hydrophobic side chains of Lys15, Leu17, Ala108, Leu110, Ser117, Thr119, and Val121. The substituted phenyl ring forms van der Waals interactions with Val17 and Ala108. The carboxylate group of the CH<sub>3</sub>CHCOOH substituent is observed to electrostatically interact with Lys15. Furthermore, a number of diphenyl structure-related derivatives have been synthesized (**15–65**, Figure 5) and tested as potent inhibitors against amyloid fibril formation. High inhibitory activity has been observed for about half of these analogs, and eight of them greatly promote tetramer dissociation into monomer.<sup>27</sup> Structure–activity relationship study shows that connecting of a carboxylate-substituted



**Figure 2** The dissociation of TTR tetramer. TTR tetramer dissociates into monomers, which can be dimerized and further tetramerized by interacting with diflunisal. The unfolded/misfolded monomers of TTR aggregate to form amyloid fibrils, which may be inhibited by inhibitors, such as diflunisal.



**Figure 3** The substructure-combinational strategy is used for producing potent and selective ATTR inhibitors (**A**). The binding model is indicated within the T4-binding pockets (**B**). The indicated structure may be considered as the possible pharmacophoric elements (**C**), and the alternative substitutions may be showed as Z, Y, and X.



**Figure 4** Biphenyl ethers act as the potent ATTR inhibitors.

hydrophilic ring to a di-halogen hydrophobic ring is essential for its potential activity in inhibiting amyloid fibril formation.

The TTR binding affinity of bromine- and iodine-substituted diphenyl compounds iododiflunisal and bromodiflunisal (**66–67**, **Figure 6**) has also been investigated that both bromine and iodine substitutions increase the binding potencies with

values of 0.85 and 0.53, respectively, calculated by  $EC_{50} T4/EC_{50}$  tested compound, compared with diflunisal with a value of 0.04 (**Table 1**).<sup>29</sup> A series of iodine-substituted biphenyls, including iododiflunisal (**68–89**, **Figure 6**), have been produced. Data from the T4 competition assay show that the ability of these iodine-substituted biphenyls to stabilize TTR has been improved significantly than that of those inhibitors





Figure 5 Continued.

without iodine atoms (Table 1).<sup>30</sup> The iodine atom in the iododiflunisal complex produces hydrophobic interactions with Leu17, Thr106, Ala108, Thr119, and Val121, occupying the P1 pocket. Studies have showed that methyl and chloro groups in the phenyl ring and carboxyl group are the necessary requirement for flurbiprofen to create high affinity and stabilization effects on binding to TTR. Flurbiprofen analogs CHF5074 (**90**, Figure 6), CHF5075 (**91**, Figure 6), CHF4795 (**92**, Figure 6), and CHF4802 (**93**, Figure 6) are also involved

in the investigation of their effects on stabilizing TTR. CHF5075 (**91**) and CHF4802 (**93**) exhibit greater activities than flurbiprofen on TTR stabilization. CHF4795 (**92**) shows a similar effect, and CHF5074 (**90**) indicates a worse effect on TTR stabilization.<sup>31</sup>

Polychlorinated biphenyls (PCBs) and hydroxylated polychlorinated biphenyls (OH-PCBs), due to their slow degradation, are known for their pollution to the environment and toxicity to humans.<sup>32-35</sup> Both PCBs and OH-PCBs bind



**Figure 5** Diphenyl structure-related derivatives act as the potent inhibitors against ATTR.


to TTR tetramer with a high affinity with  $K_i$  values of 10–140 nM, similar to the natural ligand T4 (a  $K_i$  value of 62 nM) (Table 1).<sup>36,37</sup> Expectedly, several PCBs and OH-PCBs are reported (94–123, Figure 7), and their inhibitory activities against ATTR are also measured.<sup>38,39</sup> Only 12–50% of the normal amount of fibril formation is observed after a period of 72 h incubation (PCB 3.6  $\mu$ M, TTR 3.6  $\mu$ M). Studies on the binding selectivity of PCBs and OH-PCBs for TTR in human blood plasma have been shown that compounds 102–109 bind to TTR with  $IC_{50}$  values of less than 50 nM.<sup>37</sup> In addition, OH-PCBs (compounds 110–123) competitively bind to the T4-binding sites of TTR and lower T4 levels in mice or rats.<sup>26,40,41</sup>

However, due to bioaccumulation and toxicity to the human body, PCBs and OH-PCBs are exclusively used in industry, such as lubricants and coolants.<sup>42</sup> In contrast to the higher-chlorinated congeners, the lower-chlorinated PCB congeners (LC-PCBs) are more susceptible to metabolic conversion, producing less toxicity to the human body.<sup>43</sup> Specifically, LC-PCBs may undergo oxidative metabolism and become hydroxylated LC-PCBs (OH-LC-PCBs) catalyzed by cytochrome P-450 enzymes.<sup>44</sup> LC-PCB sulfates, the further metabolites of LC-PCBs, are also artificially synthesized (124–141, Figure 8).<sup>45,46</sup> The binding potentials of several LC-PCB sulfates (compounds 125–129) and OH-LC-PCBs (compounds 137–141) to TTR have been investigated that PCB sulfates non-covalently act as the ligands with higher affinity to TTR than their respective

OH-PCB precursors. The equilibrium dissociation constants of LC-PCB sulfates in binding to TTR are in a low nanomolar range (4.8–16.8 nM), similar to that observed for T4 (4.7 nM) (Table 1).<sup>46</sup> Docking simulations provide multiple high-affinity model of binding. The lowest-energy binding conformations indicate an orientation that produces hydrogen bonding interactions between the sulfate groups and Lys15. The ortho-sulfate group appears to form hydrogen bonding with Leu110.

In addition to diphenyl ethers and biphenyls, 40 binary molecules based on 10 unique linker substructure (142–181, Figure 9) have been developed and evaluated as potent and highly selective ATTR inhibitors.<sup>23</sup> Of the 40 tested compounds, 20 compounds exhibit potent inhibitory activity against TTR aggregation with percent fibril formation (% F.F.) values of <20% (Table 2). TTR binding stoichiometry (P.S.) values are obtained by the plasma selectivity assay for the active candidate compounds. The average values of the % F.F. and P.S. are calculated and indicated as % F.F.<sub>ave</sub> and P.S.<sub>ave</sub>, respectively.<sup>26,47,48</sup> The two factors were then input into the equation below to afford an “Efficacy Score” for each linker, as indicated that higher efficacy scores correspond to more potent and selective linkers.

The results show that inhibitors with connection of two aryls by non-polar *E*-olefin or  $-CH_2-CH_2-$  exhibit higher efficacy scores (Table 2) and more potent and selective activity in inhibiting ATTR (Table 2).<sup>23</sup>




**Figure 6** Bromine- and iodine-substituted diphenyls act as the potent inhibitors against ATTR.

Furthermore, the effects of Aryl-Z with different substitution positions and substituted groups in binding to TTR using a library of 80 benzamides (compounds **182–262**, Figure 10) have been investigated. Of which, 56 compounds are involved in the evaluation of the amyloid inhibition potency, and 41 display increased potency, compared with their parent compound **182**. The capacity of 41 compounds in selectively binding to TTR in blood plasma using ex vivo plasma TTR binding selectivity assay is also studied, as indicated in Table 3.<sup>24,49,50</sup> Kinetic stabilizer binding to TTR needs to adopt similar out-of-plane aryl conformation to achieve optimal receptor–ligand

interactions. Optimal TTR–ligands interactions can also be affected by the differences in structure and energy between the preferred conformations of the free versus bound ligands. The rotational energy barriers for aryls adjacent to a linking NH group are dramatically higher than when adjacent to carbon or oxygen atoms. It is likely that other factors substantially affect ligand binding affinity and inhibitor potency, notably desolvation energies, which are difficult to predict.

Inhibitors with position 2,6; 2,5; 2; 3,4,5 and 3,5 substitutions generate excellent potency and selectivity, and the efficacy scores of which are 0.789, 0.748, 0.734, 0.697, and






**Figure 7** PCBs and OH-PCBs act as the potent inhibitors against ATTR.

0.538, respectively, higher than that of their parent compound **182** (P.S. value of 0.41). It has been shown that substitution by -OH, -Cl, -Br, -CH<sub>3</sub>, -F, -NH<sub>2</sub>, and -OCH<sub>3</sub> groups in Aryl-Z generates significant potency in interacting with TTR. The efficacy scores are 0.706, 0.667, 0.599, 0.597, 0.552, 0.525, and 0.456, respectively, and higher than that of the parent compound **182** (P.S. value of 0.41).<sup>24</sup>

Another study reports some TTR-related amyloidogenesis inhibitors composed of two aryl rings and linkers of variable chemical composition (Table 1).<sup>16,51-61</sup> The biological activity of these bisaryl molecules in inhibiting ATTR is significant, and the relative summary on different linker connections, substitution positions, and substituted groups in the two aryl rings has also been reported



**Figure 8** OH-LC-PCBs and PCB sulfates act as the potent inhibitors against ATTR.


(Figure 11). Two semi-quantitative models for predicting the optimal structures of potent and selective TTR kinetic stabilizers have been established. By comparing the efficacy scores, connection of two aryls with linkage through non-polar *E*-olefin or  $-CH_2-CH_2-$  generates more potency in interacting with TTR. The activities of Aryl-Z inhibitors with position 2.6, 2.5, and 2 substitutions are indicated as the most potency. Hydroxyl substitution on Aryl-Z inhibitors increases the most in activity. In contrast, the activity of Aryl-Z inhibitors with trifluoromethyl substitution is lowest. In addition, the substitution of 4'-hydroxyl groups on Aryl-X can improve the inhibitory activity.<sup>62</sup>

## Flavonoids and Isoflavones

Flavonoid is considered as a representative compound that exhibits inhibitory activity against TTR-related amyloid fibril formation. Nine flavonoids (263–271, Figure 12) with different amounts of phenolic hydroxyl groups have been screened for their inhibitory activity against TTR-related amyloid fibril formation. Conversion from normally folded TTR to amyloid fibrils shows that the more hydroxyl groups are substituted on flavonoids, the lower the conversion degree to amyloid fibrils is observed. As

indicated in Figure 12, compounds 267–271 exhibit the percent conversion less than 10%. Apigenin (270) has been identified as the best inhibitor in all the tested flavones, exhibiting the conversion value of 6% at the concentration of 10.8  $\mu M$  and completely inhibiting fibril formation at the concentration of 36  $\mu M$  (Table 1).<sup>60</sup>

Several natural flavonoids (272–278, Figure 12), including luteolin (272), have been tested to probe the influence of the number and position of hydroxyl groups in flavonoid scaffold on the interactions between flavonoids and TTR. The results indicated that changing the number and position of hydroxyl groups attached to the flavonoid core strongly influences flavonoid recognition by TTR. Hydrophobic interaction with Lys15 may be favorable to binding to TTR. The Lys15 side chains at the entrance of TTR orients the position of flavonoid AC rings on the center and bottom of the binding sites. The flexibility of the B ring also contributes to the binding entropy. Luteolin, being considered as a potent ATTR inhibitor, has a highest inhibitory potency against TTR disaggregation in vitro with an  $IC_{50}$  value of  $5.68 \pm 1.10 \mu M$ , lower than that of the natural ligand T4 with an  $IC_{50}$  value of  $7.14 \pm 1.08 \mu M$  (Table 1).<sup>63,64</sup>



**Figure 9** Compounds 142–181 with the different linkers as the potent inhibitors against ATTR are indicated.

**Genistein** (279, [Figure 13](#)) and its O-glucoside conjugate **genistin** (280, [Figure 13](#)), which are isoflavones found in soybeans, are excellent acid-mediated ATTR inhibitors and reduce acid-mediated fibril formation to

<10%. Additionally, these two natural products exhibit high selectivity in binding to TTR in plasma. Another two natural isoflavones from soybeans, **daidzein** (281, [Figure 13](#)) and its **O-glucoside conjugate** (282,

**Table 2** The Efficacy Scores of Compounds **142–181**

Compounds	% F. F.	P.S.	% F. F <sub>ave</sub>	P. S <sub>ave</sub>	Efficacy Scores	Compounds	% F. F.	P.S.	% F. F <sub>ave</sub>	P. S <sub>ave</sub>	Efficacy Scores
142	12%	0.13	7.8	0.66	0.510	162	80%	–	33.3	0.40	0.312
143	17%	0.11				163	44%	–			
144	1%	0.98				164	8%	0.31			
145	1%	1.41				165	1%	1.30			
146	28%	–	11.5	0.87	0.492	166	77%	–	42.8	0.25	0.238
147	15%	0.10				167	9%	0.02			
148	2%	1.10				168	79%	–			
149	1%	1.47				169	6%	0.96			
150	71%	–	22.0	0.73	0.450	170	83%	–	55.0	0.30	0.195
151	14%	0.30				171	41%	–			
152	2%	0.84				172	85%	–			
153	1%	1.78				173	11%	1.19			
154	70%	–	30.0	0.62	0.377	174	88%	–	80.3	0.15	0.152
155	48%	–				175	70%	–			
156	3%	0.88				176	81%	–			
157	1%	1.58				177	2%	0.58			
158	47%	–	29.5	0.41	0.331	178	89%	–	62.5	0	0.125
159	8%	0.13				179	43%	–			
160	61%	–				180	92%	–			
161	2%	1.51				181	26%	0.41			

**Notes:** Efficacy scores are calculated from % FF<sub>ave</sub> and P.S<sub>ave</sub>. Compounds with % F.F. values of >20% fibril formation are exclusive in the plasma selectivity assay as they are assigned with P.S. values of 0. Higher efficacy scores correspond to more potent and selective linkers.

Figure 13), exhibit lower potency in fibril aggregation inhibition as they lack the hydroxyl groups at position 5 on genistein and genistin. This suggests that the hydroxyl group at position 5 on flavonoids plays an important role in fibril aggregation inhibition.<sup>65</sup>


### β-Aminoxypropionic Acids

A series of β-aminoxypropionic acids (**283–299**, Figure 14) and their derivatives (**300–310**, Figure 14) have been synthesized and reported as TTR-related amyloid formation inhibitors.<sup>66–68</sup> These compounds contain a flexible oxime-based tether between the aromatic (aryl or fluorenyl) and acidic moieties, which are structurally distinct from the native ligand thyroxine and typical halogenated biaryl NSAID-like inhibitors and avoid off-target hormonal or anti-inflammatory activity. The aromatic ring is docked into P3 and plays a role in deciding the binding mode for this series of TTR inhibitors, and the β-aminoxyethyl chain directs the carboxylic group to Lys15. The ortho-CF<sub>3</sub> substitution on the phenyl ring is engaged in interaction with P3 residues Ala108, Leu110, Ser117, and Thr119. However, substitutions in the meta- and para-position do not interact with P3 to the same extent. Of the 28 tested compounds, six compounds (**291**, **293**, **294**, **302**,

**304**, and **305**, Figure 14) at a concentration of 3.6 μM show significant inhibition in TTR amyloidogenesis (fibril formation inhibition >50%) by using an in vitro fibril formation assay. Notably, fluorenyl compounds **293**, **294** and **304** display stronger inhibitory activities in TTR-related fibril formation (69% inhibition for **293** and **294** and 65% for **304**) than the well-known TTR amyloid inhibitor diflunisal (63% for diflunisal) (Table 1).<sup>27,68</sup> Compound **293**, the most potent inhibitor, also avoids anti-inflammatory activity and shows good selectivity in contrast to NSAID-based TTR inhibitors, determined by an in vivo carrageenan-induced paw edema assay in rats.<sup>68</sup>

### Crown Ethers and Carboranes

Of the seven lysine residues in the human transthyretin monomer, only Lys15 is located at the T4-binding site, providing a protonated amino group to form a salt bridge with the TTR stabilizers that have a ring structure.<sup>28,69–71</sup> The cyclic hexamer 18-crown-6 (**315**) is well known as a receptor of protonated amino groups of lysine residues due to its reasonably sized cavity (Table 1).<sup>70</sup> CLR01, a Lys-specific molecular tweezer with a circular three-dimensional structure (**311**, Figure 15), has been reported to inhibit the fibrillization by binding to lysine residues in



**Figure 10** Compounds 182–262 with different substitution positions of benzamides as the potent inhibitors against ATTR are indicated.

TTR protein and indicate an IC<sub>50</sub> value of 50  $\mu$ M in inhibiting the toxicity of amyloidogenic proteins in PC12 cells.<sup>72,73</sup> However, due to its high molecular weight, CLR01 may not be a favorable TTR stabilizer. Therefore, small cyclic molecules are promising to be developed as TTR-related fibrosis inhibitors.

Six crown ethers (312–317, Figure 16) containing a ring structure with different sizes are tested and identified as TTR-related amyloidogenesis inhibitors using fluorescence probes and chemical cross-linking assays. Unlike crown ethers 312 and 313 that do not produce any effects on amyloid fibril formation, the hexameric cyclization crown ether 314 significantly suppresses amyloid fibril formation at a concentration of 20 nM. In addition, crown ethers 315 and 317 are found to be the most potent candidates among the selected crown ethers, inhibiting the formation of TTR-related amyloid fibril by 58% (at a concentration of 2 mM) and 47% (at a concentration of 10 mM), respectively (Table 1).<sup>15</sup> It indicates that a

hexameric cyclization is required for crown ethers in the inhibition of TTR-related amyloid fibril formation, and the addition of a phenyl group may increase the inhibitory potency. However, the carboxyl phenyl group is more important for crown ethers 315 to bind to the allosteric sites of TTR than the cyclic polyether moiety. In addition, crown ethers 315 and 317 stabilize the TTR tetramer in a dose-dependent manner, compared with other crown ethers.<sup>74</sup>

Carboranes, being rich and untapped, have been considered as a novel class of inorganic pharmacophores, which contain a rigid skeleton of dicarba-closo-dodecaboranes. This rigid scaffolding structure affords carboranes extraordinary chemical properties, such as strong hydrophobicity, resistance to catabolism, and especially high selectivity. Furthermore, carboranes share approximately the same volume as the rotated three-dimensional aromatics.<sup>75</sup> A study on the structure and properties of carboranes shows that replacing a benzene ring in

**Table 3** The Efficacy Scores of Compounds 178–258

Compounds	% F. F.	P.S.	% F. F <sub>ave</sub>	P. S <sub>ave</sub>	Efficacy Scores	Compounds	% F. F.	P.S.	% F. F <sub>ave</sub>	P. S <sub>ave</sub>	Efficacy Scores
183	–	–	2.5	1.43	0.789	223	4%	1.56	17.0	0.94	0.538
184	1%	1.67				224	2%	1.39			
185	–	–				225	5%	1.29			
186	3%	1.73				226	4%	1.30			
187	3%	1.69				227	10%	1.02			
188	–	–				228	–	–			
189	3%	0.62				229	24%	0.05			
190	–	–				230	–	–			
191	–	–				231	–	–			
192	–	–				232	70%				
193	1%	1.01	1.3	1.27	0.748	233	9%	1.40	18.6	0.63	0.443
194	0%	1.70				234	8%	1.09			
195	1%	1.40				235	8%	0.95			
196	1%	1.46				236	12%	0.85			
197	0%	1.73				237	13%	0.68			
198	–	–				238	25%	1.21			
199	1%	1.57				239	29%	–			
200	–	–				240	34%	–			
201	–	–				241	11%	0.16			
202	5%	0.05				242	37%	–			
203	2%	1.14	8.2	1.40	0.734	243	–	–	25.0	0.65	0.413
204	2%	1.48				244	9%	1.48			
205	1%	1.56				245	10%	1.13			
206	2%	1.56				246	36%	–			
207	2%	1.39				247	45%	–			
208	3%	1.58				248	–	–			
209	2%	1.88				249	–	–			
210	3%	1.82				250	–	–			
211	64%	–				251	–	–			
212	1%	1.62				252	–	–			
213	–	–	3.0	1.16	0.697	253	21%	1.33			
214	3%	0.94				254	53%	–			
215	2%	0.87				255	53%	–			
216	3%	1.70				256	49%	–			
217	4%	1.11				257	45%	–			
218	–	–				258	27%	–			
219	–	–				259	54%	–			
220	–	–				260	50%	–			
221	–	–				261	11%	0.49			
222	–	–				262	83%	–			


**Notes:** Efficacy scores are calculated from % F<sub>ave</sub> and P<sub>S,ave</sub>. Compounds with % F.F. values of <25% fibril formation are included in the plasma selectivity assay as the P.S. values are lower than those of their parent compound **182** (% F.F. values of 26%). Higher efficacy scores correspond to more potent and selective inhibitors.

NSAIDs with the carborane moiety can improve their selectivity for TTR protein and decrease their anti-COX activity, indicating that the carborane-substituted compounds may have the potentials to be developed as ATTR inhibitors.

A group of carborane-based compounds (**318–325**, Figure 17) have been recognized as the promising

inhibitors against TTR-related amyloid formation.<sup>52,60,75</sup>

In TTR assays, compound **318** has been proven to be a moderate inhibitor against TTR-related amyloid formation with the percent fibril formation by 46% at a concentration of 3.6  $\mu$ M. Consistently, compounds **322** and **325** have been identified as the most potent inhibitors with the percent fibril formation by 22% and 15%, respectively.<sup>76</sup>



**Figure 11** Summary of the structure–activity relationships of small molecule ATTR inhibitors composed of two aryl rings and variable linkers.

## Oxazoles

Aryl oxazoles bearing a carboxyl group at C-4 have been demonstrated to be an efficient class in inhibiting TTR amyloidogenesis. Substitution of ethyl, propyl, or CF<sub>3</sub> group at C-5 may significantly enhance the inhibiting activity. In contrast, the substitution of a 3,5-dichlorophenyl at C-2 on the oxazole ring dramatically reduces its activity. Compounds **326** and **327** (Figure 18) have been shown to inhibit TTR activity and fibril formation at the dose of 3.6 μM and 7.2 μM, respectively (Table 1).<sup>77</sup>

## γ-Mangostin


γ-Mangostin (**328**, Figure 18), a xanthone derivative isolated from mangosteen, has been reported to bind to T4-binding sites directly, stabilize TTR tetramer, and inhibit the amyloid fibril formation of V30M amyloidogenic TTR with EC<sub>50</sub> value of 7 ± 0.6 μM (Table 1).<sup>78</sup>

## Quinoline Derivatives


A library of quinolone derivatives has been synthesized. Among these quinolone derivatives, compound **329** has been screened to dock into the T4-binding sites of TTR and be the most potent in inhibiting TTR fibril formation with an IC<sub>50</sub> value of 1.49 μM against wild-type TTR and 1.63 μM against V30M TTR variant. Intravenous injection of 2 mg/kg compound **329** and **330** (Figure 18) produces the peak plasma concentration (C<sub>max</sub>) in rats as 3.107 and 2.381 μg/mL, respectively, and half-life (T<sub>1/2</sub>) as 2.710 and 2.745 h, respectively (Table 1).<sup>79</sup>

## TTR-Targeting RNAi

RNA interference (RNAi) is a clinically validated technology, being a promising approach for managing ATTR amyloidosis. TTR-targeting siRNAs have been evaluated in hTTR V30M HSF1± mice. Knockdown of TTR



**Figure 12** Flavonoids act as small potent inhibitors against ATTR.



**Figure 13** Isoflavones act as small potent inhibitors against ATTR.

expression by RNAi significantly inhibits the deposition of TTR and promotes regression of existing TTR deposits in pathological tissues, showing a greater activity than that of tafamidis and highlighting the potential of RNAi.<sup>80</sup> TTR siRNA promotes clearance of TTR deposition in the extracellular matrix of meninges and brain blood vessels. However, the cerebrospinal fluid TTR concentration is unchanged, although it is declined significantly in the

blood. This indicates that TTR-targeting siRNA may not affect the neuroprotective activity of TTR in the central nervous system.<sup>81</sup>

### ATTR Inhibitors by Disaggregating TTR-Related Amyloid fibrils

In addition to stabilizer of TTR tetramers, small molecules that directly disaggregate amyloid fibrils have been



developed to manage ATTR disease. Animal experiments show that doxycycline (**331**, Figure 19) inhibits the formation of amyloid fibers and destroys the deposited fibers, exhibiting good effects on FAP and light-chain amyloidosis.<sup>82,83</sup> Tauroursodeoxycholic acid (TUDCA) (**332**, Figure 19) can reduce the deposition of TTR precursor fibers, which is often combined with doxycycline to significantly promote the deposition of amyloid substances and non-fibrous TTR oligomers.<sup>84,85</sup>

Several natural products have been analyzed for their activity in inducing amyloid fibril disaggregation, as revealed that gossypol, rottlerin, and hematoxylin (**333–335**, Figure 20) disrupt the pre-formed amyloid fibril. The competitive assays are involved to judge that, except hematoxylin, both gossypol and rottlerin competitively bind to the T4-binding site. Collectively, hematoxylin is an amyloid fibril disrupter, and gossypol and rottlerin are dual inhibitors.<sup>7</sup> Indeed, some biphenyl ether compounds have been shown to exhibit TTR stabilization and fibril disruption activities.<sup>18</sup>


## Clinical Perspectives

The familiar NSAID diflunisal (**13**, Figure 5), which may bind to the T4-binding site of TTR, stabilize the tetramer, and inhibit the amyloidogenesis, has already been approved as a prescription drug in more than 40 countries.<sup>27,28,86–88</sup> In addition, tafamidis (**336**, Figure 21), an oral small molecule inhibitor, has been developed for the treatment of FAP by stabilizing the TTR tetramer.<sup>89–91</sup> However, tafamidis is exclusively effective in the early stage of FAP and currently available in Europe, Japan, Mexico, and Argentina till 2018.<sup>92</sup> In the management of TTR amyloid cardiomyopathy, tafamidis has been showed to be associated with lower all-cause mortality (29.5%) than placebo (42.9%). At month 30, tafamidis is indicated with a lower rate of decline in distance for the 6-min walk test and in KCCQ-OS score, reducing cardiovascular-related hospitalizations and the decline in functional capacity and life quality.<sup>93</sup> Pfizer is now working on the application for a US listing of tafamidis, which are expected to be approved by the end of 2019. Inotersen, an antisense oligonucleotide, has been recently demonstrated to improve disease course and life quality in the early hereditary transthyretin amyloidosis polyneuropathy by reducing the production of transthyretin.<sup>94</sup> Inotersen has been clinically approved in the European Union for the management of adult patients with hATTR-PN on


August 20, 2018.<sup>95</sup> And now it is accepted by USA, European Union, and Canada.<sup>94</sup>

Epigallocatechin-3-gallate (EGCG) (**337**, Figure 21) and resveratrol (**338**, Figure 21), two polyphenols isolated from green tea and grape skins, respectively, have been shown to stabilize TTR tetramers.<sup>96,97</sup> EGCG may inhibit the deposition of TTR pre-fiber by up to 50% and decompose amyloid.<sup>98</sup> In addition, EGCG stabilizes myocardial mass in wtATTR-CM patients with good tolerance and no major safety concerns.<sup>99,100</sup> Therefore, EGCG has been expected to be developed for the treatment of amyloid cardiomyopathy. In vitro, studies have shown that resveratrol may promote free monomers to form a tetramer and decrease the toxicity of pre-fiber TTR molecules.<sup>97</sup> However, the clinical application of resveratrol is limited, due to its poor drug-like physicochemical and ADMET properties.<sup>101,102</sup>

Reduction or stop of endogenous TTR protein production is also an effective strategy to prevent the further progression of ATTR disease, as TTR has been shown to be a non-essential protein transporter of T4.<sup>103</sup> Oligonucleotides, such as patisiran, revusiran, and ASOs, are molecules that reduce the production of mutated proteins, thus modifying ATTR disease outcome.<sup>104</sup> Patisiran (ALN-TTR02) and revusiran (ALN-TTRsc), the two siRNA molecules currently under clinical investigation, contain a double-stranded RNA that targets wild-type and mutated TTR proteins, inhibit the synthesis of TTR, and promote the degradation of surrounding amyloid.<sup>105–107</sup> Specifically, patisiran is a siRNA encapsulated in a lipid nanoparticle and binds to the mutant and wild-type TTR mRNA, reducing the level of TTR in the blood.<sup>108</sup> The results from Phase III clinical trials show that intravenous administration of patisiran significantly reduced blood TTR level at an optimal dose of 0.3 mg/kg of body weight for every 3 weeks.<sup>109</sup> Promisingly, patisiran has been approved by the FDA.<sup>94</sup> Revusiran, another one siRNA developed by Alnylam Company, is conjugated with *N*-acetylgalactosamine.<sup>106</sup> Unfortunately, revusiran was halted at phase III clinical trials, due to more deaths in the treatment group.<sup>110</sup> ASOs, an antisense oligonucleotide developed by Isis pharmaceuticals, have been used to treat amyloid cardiomyopathy. Combination of ASOs and TTR mRNA inhibits the production of mutant TTR and wild-type TTR. After 4 weeks of subcutaneous injection, the inhibitory rate may reach over 90%, indicating that this strategy can be applied for the treatment of hereditary ATTR and SSA.<sup>111</sup> In addition, the neuro-energy




**Figure 14**  $\beta$ -aminoxypropionic acids act as small potent inhibitors against ATTR.




**Figure 15** Lys-specific molecular tweezer CLR01 interacts with Lys by forming a salt bridge.

turbulence and living quality in FAP patients may be improved by ASOs in phase III clinical trials.<sup>112</sup> Tolcapone (SOM0266), a catechol-*O*-methyltransferase


inhibitor in Phase II–III in the clinical trial, has been used as an adjunct to levodopa/carbidopa for management of Parkinson's diseases. Tolcapone, better than tafamidis,




**Figure 16** Crown ethers act as small potent inhibitors against ATTR.




**Figure 17** Carboranes act as small potent inhibitors against ATTR.




**Figure 18** Structures of oxazoles,  $\gamma$ -Mangostin, and quinolone derivatives.



**Figure 19** Structures of doxycycline and TUDCA.



**Figure 20** Structures of gossypol, rottlerin, and hematoxilin.




**Figure 21** Structures of tafamidis, EGCG, and resveratrol.

may dock into the T4-binding sites of wild-type TTR and the V122I cardiomyopathy-associated TTR variant with enthalpically driven optimization, inhibiting their aggregation with  $EC_{50}$  values of  $1.50 \pm 0.12 \mu\text{M}$  and  $4.72 \pm 0.45 \mu\text{M}$ , respectively (Table 1).<sup>113</sup> In addition, tolcapone also inhibits the aggregation of the leptomenigeal-associated A25T-TTR variant. Tolcapone increases 52% of TTR stabilization at the dose of 200 mg within 2 h in phase A and increases 38.8% at the dose of 100 mg.<sup>114</sup> In vitro,

tolcapone partially ameliorates the activation of caspase-3 induced by Y78F-TTR oligomers in RN22 cells.<sup>115</sup>

## Conclusion

In this article, the different types of ATTR inhibitors and a summary of the structure–activity relationship of some compounds have been reviewed (Figure 22). Bisaryl structures with a linker, such as diphenyl ethers and biphenyl compounds, functions as the largest class



**Figure 22** The possible structure–activity relationship of TTR amyloidogenesis inhibitors, including bisaryl structures with a linker, flavonoids and isoflavones,  $\beta$ -minoxypropionic acids, crown ethers and carboranes, and oxazoles.

of ATTR inhibitors. This class of compounds is mainly docked into the two T4 active pockets of TTR, maintaining the stability of the TTR tetramer, and the spatial distance between the two active pockets determines the length of the biphenyl linker. In addition, the types and position of substituents on the two aryl rings also affect the activity. Inhibitors that inhibit TTR amyloid fibril formation play an important role in the treatment of ATTR. Flavonoids and isoflavones, represented by luteolin and genistein, have been considered as the potential inhibitors against TTR protein fiber formation.  $\beta$ -aminoxypropionic acid, a class of well-known amyloid fibrinogen formation inhibitors, has the distinct advantage of avoiding off-target and producing incoherent anti-inflammatory activity. Crown ethers and carboranes also show good selectivity contrast to NSAID-based TTR inhibitors. Amyloid fibril disrupters are the novel therapeutic compounds, providing a new strategy for the management of ATTR. Some molecules that directly disaggregate amyloid fibrils have been developed. For example, antibiotic doxycycline and natural product hematoxilin have been shown the surprising disaggregation activity against amyloid fibrils.

## Data Sharing Statement

The experimental data used to support the findings of this study are included within the article.

## Acknowledgments

This study was financially supported by the National Natural Science Foundation of China (81660371, 81860388, 81860261, and 81960883), The Youth Jinggang Scholar Program in Jiangxi Province, and Innovative Teamwork Project of Gannan Medical University (TD201707).

## Author Contributions

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

## Disclosure

The authors declare no conflicts of interest in this work.

## References

- Saraiva MJ, Magalhaes J, Ferreira N, Almeida MR. Transthyretin deposition in familial amyloidotic polyneuropathy. *Curr Med Chem.* 2012;19(15):2304–2311. doi:10.2174/092986712800269236
- Sebastiao MP, Lamzin V, Saraiva MJ, Damas AM. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. *J Mol Biol.* 2001;306(4):733–744. doi:10.1006/jmbi.2000.4415
- Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. *Eur J Biochem.* 1997;249(3):662–668. doi:10.1111/j.1432-1033.1997.00662.x
- Terazaki H, Ando Y, Misumi S, et al. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. *Biochem Biophys Res Commun.* 1999;264(2):365–370. doi:10.1006/bbrc.1999.1514

5. Sekijima Y, Hammarstrom P, Matsumura M, et al. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. *Lab Invest.* 2003;83(3):409–417. doi:10.1097/01.LAB.0000059937.11023.1F
6. Robinson LZ, Reixach N. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case. *Biochemistry.* 2014;53(41):6496–6510. doi:10.1021/bi500739q
7. Yokoyama T, Mizuguchi M. Inhibition of the amyloidogenesis of transthyretin by natural products and synthetic compounds. *Biol Pharm Bull.* 2018;41(7):979–984. doi:10.1248/bpb.b18-00166
8. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. *J Mol Biol.* 1978;121(3):339–356. doi:10.1016/0022-2836(78)90368-6
9. Naylor HM, Newcomer ME. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. *Biochemistry.* 1999;38(9):2647–2653. doi:10.1021/bi982291i
10. Choi S, Connelly S, Reixach N, Wilson IA, Kelly JW. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. *Nat Chem Biol.* 2010;6(2):133–139. doi:10.1038/nchembio.281
11. Ciccone L, Fruchart-gaillard C, Mourier G, et al. Copper mediated amyloid- $\beta$  binding to transthyretin. *Sci Rep.* 2018;8(1):13744. doi:10.1038/s41598-018-31808-5
12. Yee AW, Aldeghi M, Blakeley MP, et al. A molecular mechanism for transthyretin amyloidogenesis. *Nat Commun.* 2019;10(1):925. doi:10.1038/s41467-019-08609-z
13. Saelices L, Sievers SA, Sawaya MR, Eisenberg DS. Crystal structures of amyloidogenic segments of human transthyretin. *Protein Sci.* 2018;27(7):1295–1303. doi:10.1002/pro.3420
14. Zhang J, Grundström C, Brännström K, et al. Interspecies variation between fish and human transthyretins in their binding of thyroid-disrupting chemicals. *Environ Sci Technol.* 2018;52(20):11865–11874.
15. Yokoyama T, Mizuguchi M. Crown ethers as transthyretin amyloidogenesis inhibitors. *J Med Chem.* 2019;62(4):2076–2082. doi:10.1021/acs.jmedchem.8b01700
16. Petrassi HM, Klabunde T, Sacchettini J, Kelly JW. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. *J Am Chem Soc.* 2000;122(10):2178–2192. doi:10.1021/ja993309v
17. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. *Science.* 2003;299(5607):713–716. doi:10.1126/science.1079589
18. Gupta S, Chhibber M, Sinha S, Surolia A. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates. *J Med Chem.* 2007;50(23):5589–5599. doi:10.1021/jm0700159
19. Ortore G, Martinelli A. Identification of transthyretin fibril formation inhibitors using structure-based virtual screening. *ChemMedChem.* 2017;12(16):1327–1334. doi:10.1002/cmdc.201700051
20. Greene MJ, Klimtchuk ES, Seldin DC, Berk JL, Connors LH. Cooperative stabilization of transthyretin by clusterin and diflunisal. *Biochemistry.* 2015;54(2):268–278. doi:10.1021/bi5011249
21. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. *Transl Neurodegener.* 2014;3:19. doi:10.1186/2047-9158-3-19
22. Choi S, Reixach N, Connelly S, Johnson SM, Wilson IA, Kelly JW. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. *J Am Chem Soc.* 2010;132(4):1359–1370. doi:10.1021/ja908562q
23. Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. *J Med Chem.* 2008;51(20):6348–6358. doi:10.1021/jm800435s
24. Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. *J Med Chem.* 2009;52(4):1115–1125. doi:10.1021/jm801347s
25. Wojtczak A, Cody V, Luft J, Pangborn W. Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 Å resolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites. *Acta Crystallogr D Biol Crystallogr.* 2001;57(Pt8):1061–1070. doi:10.1107/S0907444901007235
26. Purkey HE, Dorrell MI, Kelly JW. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. *Proc Natl Acad Sci U S A.* 2001;98(10):5566–5571. doi:10.1073/pnas.091431798
27. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. *J Med Chem.* 2004;47(2):355–374. doi:10.1021/jm030347n
28. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. *Nat Struct Biol.* 2000;7(4):312–321. doi:10.1038/74082
29. Almeida MR, Macedo B, Cardoso I, et al. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. *Biochem J.* 2004;381(Pt 2):351–356. doi:10.1042/BJ20040011
30. Mairal T, Nieto J, Pinto M, et al. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. *PLoS One.* 2009;4(1):e4124. doi:10.1371/journal.pone.0004124
31. Loconte V, Menozzi I, Ferrari A, et al. Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin. *J Struct Biol.* 2019;208(2):165–173. doi:10.1016/j.jsb.2019.08.011
32. Safe S. Toxicology, structure-function relationship, and human and environmental health impacts of polychlorinated biphenyls: progress and problems. *Environ Health Perspect.* 1993;100:259–268. doi:10.1289/ehp.93100259
33. Safe SH. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. *Crit Rev Toxicol.* 1994;24(2):87–149.
34. Safe S. Human toxicology of chlorinated organic micropollutants. In: Hester RE, Harrison RM, editors. *Chlorinated Organic Micropollutants.* Vol. 6. The Royal Society of Chemistry; 1996:73–88.
35. Koss G, Wölffe D. Chapter 29 - Dioxin and dioxin-like polychlorinated hydrocarbons and biphenyls. In: Marquardt H, Schäfer SG, McClellan R, Welsch F, editors. *Toxicology.* San Diego: Academic Press; 1999:699–728.
36. Cheek AO, Kow K, Chen J, McLachlan JA. Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. *Environ Health Perspect.* 1999;107(4):273–278. doi:10.1289/ehp.99107273
37. Chauhan KR, Kodavanti PRS, McKinney JD. Assessing the role of ortho-substitution on polychlorinated biphenyl binding to transthyretin, a thyroxine transport protein. *Toxicol Appl Pharmacol.* 2000;162(1):10–21. doi:10.1006/taap.1999.8826
38. Lehmler HJ, Robertson LW. Synthesis of hydroxylated PCB metabolites with the Suzuki-coupling. *Chemosphere.* 2001;45(8):1119–1127. doi:10.1016/S0045-6535(01)00052-2

39. Purkey HE, Palaninathan SK, Kent KC, et al. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. *Chem Biol.* 2004;11(12):1719–1728. doi:10.1016/j.chembiol.2004.10.009
40. Sandau CD, Meerts IATM, Letcher RJ, et al. Identification of 4-hydroxyheptachlorostyrene in polar bear plasma and its binding affinity to transthyretin: a metabolite of octachlorostyrene? *Environ Sci Technol.* 2000;34(18):3871–3877. doi:10.1021/es001134f
41. Morse DC, Wehler EK, Wesseling W, Koeman JH, Brouwer A. Alterations in rat brain thyroid hormone status following pre- and postnatal exposure to polychlorinated biphenyls (Aroclor 1254). *Toxicol Appl Pharmacol.* 1996;136(2):269–279. doi:10.1006/taap.1996.0034
42. Margaret O. James. Polychlorinated Biphenyls: Metabolism and Metabolites. In: Robertson LW, Hansen LG, editors. *Recent Advances in Environmental Toxicology and Health Effects*. University Press of Kentucky; 2001:35–46.
43. Robertson LW, Ludewig G. Polychlorinated biphenyl (PCB) carcinogenicity with special emphasis on airborne PCBs. *Air Qual Control.* 2011;71(1–2):25–32.
44. Letcher RJ, Klasson-wehler E, Bergman A. Methyl sulfone and hydroxylated metabolites of polychlorinated biphenyls. In: Hutzinger O, Paasivirta J, editors. *Volume 3 Anthropogenic Compounds Part K*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2000:315–359.
45. Li X, Parkin S, Duffel MW, Robertson LW, Lehmler H-J. An efficient approach to sulfate metabolites of polychlorinated biphenyls. *Environ Int.* 2010;36(8):843–848. doi:10.1016/j.envint.2009.02.005
46. Grimm FA, Lehmler H-J, He X, Robertson LW, Duffel MW. Sulfated metabolites of polychlorinated biphenyls are high-affinity ligands for the thyroid hormone transport protein transthyretin. *Environ Health Perspect.* 2013;121(6):657–662. doi:10.1289/ehp.1206198
47. Lashuel HA, Wurth C, Woo L, Kelly JW. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. *Biochemistry.* 1999;38(41):13560–13573. doi:10.1021/bi991021c
48. Johnson SM, Connelly S, Wilson IA, Kelly JW. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. *J Med Chem.* 2008;51(2):260–270. doi:10.1021/jm0708735
49. Glaser K, Sung ML, O’neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. *Eur J Pharmacol.* 1995;281(1):107–111. doi:10.1016/0014-2999(95)00302-2
50. Inoue A, Yamakawa J, Yukioka M, Morisawa S. Filter-binding assay procedure for thyroid hormone receptors. *Anal Biochem.* 1983;134(1):176–183. doi:10.1016/0003-2697(83)90280-4
51. Oza VB, Petrassi HM, Purkey HE, Kelly JW. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. *Bioorg Med Chem Lett.* 1999;9(1):1–6. doi:10.1016/S0960-894X(98)00696-9
52. Baures PW, Oza VB, Peterson SA, Kelly JW. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. *Bioorg Med Chem.* 1999;7(7):1339–1347. doi:10.1016/S0968-0896(99)00066-8
53. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. *Lab Invest.* 2004;84(5):545–552. doi:10.1038/labinvest.3700059
54. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamskiwerner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidosis. *Acc Chem Res.* 2005;38(12):911–921. doi:10.1021/ar020073i
55. Green NS, Palaninathan SK, Sacchettini JC, Kelly JW. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. *J Am Chem Soc.* 2003;125(44):13404–13414. doi:10.1021/ja030294z
56. Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW. Kinetic stabilization of an oligomeric protein by a single ligand binding event. *J Am Chem Soc.* 2005;127(15):5540–5551. doi:10.1021/ja042929f
57. Petrassi HM, Johnson SM, Purkey HE, et al. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. *J Am Chem Soc.* 2005;127(18):6662–6671. doi:10.1021/ja044351f
58. Johnson SM, Petrassi HM, Palaninathan SK, et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. *J Med Chem.* 2005;48(5):1576–1587. doi:10.1021/jm049274d
59. Razavi H, Palaninathan SK, Powers ET, et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. *Angew Chem Int Ed Engl.* 2003;42(24):2758–2761. doi:10.1002/anie.200351179
60. Baures PW, Peterson SA, Kelly JW. Discovering transthyretin amyloid fibril inhibitors by limited screening. *Bioorg Med Chem.* 1998;6(8):1389–1401. doi:10.1016/S0968-0896(98)00130-8
61. Ferreira N, Saraiva MJ, Almeida MR. Uncovering the neuroprotective mechanisms of curcumin on transthyretin amyloidosis. *Int J Mol Sci.* 2019;20:6. doi:10.3390/ijms20061287
62. Connelly S, Mortenson DE, Choi S, et al. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. *Bioorg Med Chem Lett.* 2017;27(15):3441–3449. doi:10.1016/j.bmcl.2017.05.080
63. Trivella DBB, Dos Reis CV, Lima LMTR, Foguel D, Polikarpov I. Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. *J Struct Biol.* 2012;180(1):143–153. doi:10.1016/j.jsb.2012.07.008
64. Iakovleva I, Begum A, Pokrzywa M, Walfridsson M, Sauereriksson AE, Olofsson A. The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response. *PLoS One.* 2015;10(5):e0128222. doi:10.1371/journal.pone.0128222
65. Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. *Proc Natl Acad Sci U S A.* 2005;102(41):14545–14550. doi:10.1073/pnas.0501609102
66. Macchia B, Balsamo A, Lapucci A, et al. Molecular design, synthesis, and anti-inflammatory activity of a series of beta-aminoxypropionic acids. *J Med Chem.* 1990;33(5):1423–1430. doi:10.1021/jm00167a023
67. Balsamo A, Bertini S, Gervasi G, et al. Enantiopure 3-(arylmethylidene)aminoxy-2-methylpropionic acids: synthesis and anti-inflammatory properties. *Eur J Med Chem.* 2001;36(10):799–807. doi:10.1016/S0223-5234(01)01275-2
68. Palaninathan SK, Mohamedmohaideen NN, Orlandini E, et al. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis. *PLoS One.* 2009;4(7):e6290. doi:10.1371/journal.pone.0006290
69. Oshima T, Suetsugu A, Baba Y. Extraction and separation of a lysine-rich protein by formation of supramolecule between crown ether and protein in aqueous two-phase system. *Anal Chim Acta.* 2010;674(2):211–219. doi:10.1016/j.aca.2010.06.039
70. Lee -C-C, Maestre-reyna M, Hsu K-C, et al. Crowning proteins: modulating the protein surface properties using crown ethers. *Angew Chem Int Ed Engl.* 2014;53(48):13054–13058. doi:10.1002/anie.201405664
71. Tomar D, Khan T, Singh RR, et al. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites. *PLoS One.* 2012;7(9):e43522. doi:10.1371/journal.pone.0043522

72. Sinha S, Lopes DHJ, Du Z, et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. *J Am Chem Soc.* 2011;133(42):16958–16969. doi:10.1021/ja206279b
73. Ferreira N, Pereira-henriques A, Attar A, et al. Molecular tweezers targeting transthyretin amyloidosis. *Neurotherapeutics.* 2014;11(2):450–461. doi:10.1007/s13311-013-0256-8
74. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. *Biochemistry.* 1992;31(36):8654–8660. doi:10.1021/bi00151a036
75. Julius RL, Farha OK, Chiang J, Perry LJ, Hawthorne MF. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborene pharmacophores. *Proc Natl Acad Sci U S A.* 2007;104(12):4808–4813. doi:10.1073/pnas.0700316104
76. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. *Proc Natl Acad Sci U S A.* 1996;93(26):15051–15056. doi:10.1073/pnas.93.26.15051
77. Razavi H, Powers ET, Purkey HE, et al. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. *Bioorg Med Chem Lett.* 2005;15(4):1075–1078. doi:10.1016/j.bmcl.2004.12.022
78. Yokoyama T, Ueda M, Ando Y, Mizuguchi M. Discovery of  $\gamma$ -mangostin as an amyloidogenesis inhibitor. *Sci Rep.* 2015;5:13570. doi:10.1038/srep13570
79. Kim B, Park H, Lee SK, et al. Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors. *Eur J Med Chem.* 2016;123:777–787. doi:10.1016/j.ejmech.2016.08.003
80. Butler JS, Chan A, Costelha S, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. *Amyloid.* 2016;23(2):109–118. doi:10.3109/13506129.2016.1160882
81. Goncalves P, Martins H, Costelha S, Maia LF, Saraiva MJ. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. *Amyloid.* 2016;23(4):249–253. doi:10.1080/13506129.2016.1256282
82. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. *FASEB J.* 2006;20(2):234–239. doi:10.1096/fj.05-4509com
83. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. *Blood.* 2011;118(25):6610–6617. doi:10.1182/blood-2011-04-351643
84. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. *J Transl Med.* 2010;8:74. doi:10.1186/1479-5876-8-74
85. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a Phase II study. *Amyloid.* 2012;19(Suppl 1):34–36. doi:10.3109/13506129.2012.678508
86. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. *Amyloid.* 2006;13(4):236–249. doi:10.1080/13506120600960882
87. Tojo K, Sekijima Y, Kelly JW, Ikeda S-I. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. *Neurosci Res.* 2006;56(4):441–449. doi:10.1016/j.neures.2006.08.014
88. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. *J Clin Pharm Ther.* 2014;39(3):225–233. doi:10.1111/jcpt.2014.39.issue-3
89. Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. *J Neurol.* 2013;260(11):2802–2814. doi:10.1007/s00415-013-7051-7
90. Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. *J Neurol.* 2016;263(5):916–924. doi:10.1007/s00415-016-8064-9
91. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. *Proc Natl Acad Sci U S A.* 2012;109(24):9629–9634. doi:10.1073/pnas.1121005109
92. Waddington Cruz M, Benson MD. A review of tafamidis for the treatment of transthyretin-related amyloidosis. *Neurol Ther.* 2015;4(2):61–79. doi:10.1007/s40120-015-0031-3
93. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med.* 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689
94. Mathew V, Wang AK. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. *Drug Des Devel Ther.* 2019;13:1515–1525. doi:10.2147/DDDT.S162913
95. Keam SJ. Inotersen: first global approval. *Drugs.* 2018;78(13):1371–1376. doi:10.1007/s40265-018-0968-5
96. Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. *Clin Res Cardiol.* 2010;99(8):483–490. doi:10.1007/s00392-010-0142-x
97. Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. *Biochem Biophys Res Commun.* 2011;410(4):707–713. doi:10.1016/j.bbrc.2011.04.133
98. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “In vivo” evidence from FAP mice models. *PLoS One.* 2012;7(1):e29933. doi:10.1371/journal.pone.0029933
99. Aus Dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. *Drug Des Devel Ther.* 2015;9:6319–6325.
100. Cappelli F, Martone R, Taborchi G, et al. Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study. *Intern Emerg Med.* 2018;13(6):873–880. doi:10.1007/s11739-018-1887-x
101. Andrade S, Ramalho MJ, Pereira M, Loureiro JA. Resveratrol brain delivery for neurological disorders prevention and treatment. *Front Pharmacol.* 2018;9:1261. doi:10.3389/fphar.2018.01261
102. Saqib U, Kelley TT, Panguluri SK, et al. Polypharmacology or promiscuity? Structural interactions of resveratrol with its bandwagon of targets. *Front Pharmacol.* 2018;9:1201. doi:10.3389/fphar.2018.01201
103. Palha JA, Hays MT, Morreale de Escobar G, Episkopou V, Gottesman ME, Saraiva MJ. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. *Am J Physiol.* 1997;272(3 Pt 1):E485–E493. doi:10.1152/ajpendo.1997.272.3.E485
104. Niemietz C, Chandhok G, Schmidt H. Therapeutic oligonucleotides targeting liver disease: TTR amyloidosis. *Molecules.* 2015;20(10):17944–17975. doi:10.3390/molecules201017944
105. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. *Cell Metab.* 2018;27(4):714–739. doi:10.1016/j.cmet.2018.03.004
106. Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. *Nucleic Acids Res.* 2018;46(4):1584–1600. doi:10.1093/nar/gkx1239
107. Rossor AM, Reilly MM, Sleight JN. Antisense oligonucleotides and other genetic therapies made simple. *Pract Neurol.* 2018;18(2):126–131. doi:10.1136/practneurol-2017-001764



108. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. *N Engl J Med.* 2013;369(9):819–829. doi:10.1056/NEJMoa1208760
109. Adams D, Gonzalez-duarte A, O'riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *N Engl J Med.* 2018;379(1):11–21. doi:10.1056/NEJMoa1716153
110. Garber K. Alnylam terminates revusiran program, stock plunges. *Nat Biotechnol.* 2016;34(12):1213–1214. doi:10.1038/nbt1216-1213
111. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. *Amyloid.* 2012;19(Suppl 1):43–44. doi:10.3109/13506129.2012.673140
112. Hayashi Y, Jono H. Recent advances in oligonucleotide-based therapy for transthyretin amyloidosis: clinical impact and future prospects. *Biol Pharm Bull.* 2018;41(12):1737–1744. doi:10.1248/bpb.b18-00625
113. Sant'anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. *Nat Commun.* 2016;7:10787. doi:10.1038/ncomms10787
114. Gamez J, Salvado M, Reig N, et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. *Amyloid.* 2019;26(2):74–84. doi:10.1080/13506129.2019.1597702
115. Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. *FEBS Lett.* 2011;585(15):2424–2430. doi:10.1016/j.febslet.2011.06.030

## Drug Design, Development and Therapy

Dovepress

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>